{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:18:32Z","timestamp":1770041912966,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This single-arm phase 3 study was conducted to confirm the results of our phase 2 study of bendamustine (B)-rituximab (R) in patients\u00a0with relapsed\/refractory diffuse large B cell lymphoma (rrDLBCL). The primary endpoint was overall response rate (ORR). Autologous stem cell transplantation-ineligible rrDLBCL patients with\u2009\u2264\u20092 prior chemotherapy regimens received R 375\u00a0mg\/m<jats:sup>2<\/jats:sup> IV on day 1 and B 120\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day IV on days 2 and 3 every 21\u00a0days up to 6 cycles. Thirty-eight patients with a median age of 74\u00a0years (range, 43\u201386) received BR. The ORR and complete response rates were 76.3% and 47.4%, respectively. With a median follow-up of 19.5\u00a0months including long-term follow-up, median progression-free survival was 11.9\u00a0months. Median OS was 29.2\u00a0months. Discontinuation of treatment due to Gr3-5 TEAE was observed among 13 of 38 patients (34.2%). One patient with cytomegalovirus enterocolitis died during follow-up. This BR regimen was confirmed to be effective and tolerable in studied patients. ClinicalTrials.gov Identifier: NCT03372837 registered on 14 December 2017, NCT04354402 registered on 21 April, 2020.<\/jats:p>","DOI":"10.1007\/s00277-022-04801-2","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T17:01:47Z","timestamp":1646413307000},"page":"979-989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"101","author":[{"given":"Kayoko","family":"Murayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"4801_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164:536\u2013545. https:\/\/doi.org\/10.1111\/bjh.12659","journal-title":"Br J Haematol"},{"key":"4801_CR2","doi-asserted-by":"publisher","unstructured":"Fan L, Li L, Zhou Y, et al. 2017 Rituximab-based therapy in newly diagnosed diffuse large B-cell lymphoma patients: individualized risk-adapted therapy approach using molecular subtypes. J Hematol. 2017;6:33\u201343. https:\/\/doi.org\/10.14740\/jh320w","DOI":"10.14740\/jh320w"},{"key":"4801_CR3","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1634\/theoncologist.2018-0603","volume":"24","author":"A Broccoli","year":"2019","unstructured":"Broccoli A, Casadei B, Chiappella A et al (2019) Lenalidomide in pretreated patients with diffuse large B-cell lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Oncologist 24:1246\u20131252. https:\/\/doi.org\/10.1634\/theoncologist.2018-0603","journal-title":"Oncologist"},{"key":"4801_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW (2011) Relapsed\/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011:498\u2013505. https:\/\/doi.org\/10.1182\/asheducation-2011.1.498","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4801_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1349-7006.2007.00662.x","volume":"99","author":"Y Oki","year":"2008","unstructured":"Oki Y, Ogura M, Kato H et al (2008) Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. Cancer Sci 99:179\u2013184. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00662.x","journal-title":"Cancer Sci"},{"key":"4801_CR6","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T et al (2013) Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 31:2103\u20132109. https:\/\/doi.org\/10.1200\/JCO.2012.46.5203","journal-title":"J Clin Oncol"},{"key":"4801_CR7","unstructured":"NCCN. 2021 NCCN guidelines on B-cell lymphomas; [cited 2021 May]. Available from: <https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480>."},{"key":"4801_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38:155\u2013165. https:\/\/doi.org\/10.1200\/JCO.19.00172","journal-title":"J Clin Oncol"},{"key":"4801_CR9","unstructured":"SH Swerdlow E Campo NL Harris Eds et al 2008 WHO classification of tumours of haematopoietic and lymphoid tissues 2 4 IARC Press Lyon (France)"},{"key":"4801_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"4801_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdh176","volume":"15","author":"K Tobinai","year":"2004","unstructured":"Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821\u2013830. https:\/\/doi.org\/10.1093\/annonc\/mdh176","journal-title":"Ann Oncol"},{"key":"4801_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","volume":"57","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Brugger W, Damaj G et al (2016) Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update. Leuk Lymphoma 57:766\u2013782. https:\/\/doi.org\/10.3109\/10428194.2015.1099647","journal-title":"Leuk Lymphoma"},{"key":"4801_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","volume":"93","author":"JL Vacirca","year":"2014","unstructured":"Vacirca JL, Acs PI, Tabbara IA et al (2014) Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 93:403\u2013409. https:\/\/doi.org\/10.1007\/s00277-013-1879-x","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04801-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04801-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T09:07:50Z","timestamp":1649408870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04801-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4801"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04801-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Hokkaido University Hospital, Akita University Hospital, Tohoku University Hospital, Yamagata University Hospital, Fukushima Medical University Hospital, Dokkyo Medical University Hospital, Mito Medical Center, Gunma University Hospital, Gunma Prefectural Cancer Center, National Cancer Center Hospital, Cancer Institute Hospital, NTT Medical Center Tokyo, Aichi Cancer Center, Nagoya Medical Center, University Hospital Kyoto Prefectural University of Medicine, Osaka City University Hospital, Kindai University Hospital, Chugoku Central Hospital, Matsuyama Red Cross Hospital, Shimane University Hospital, Kyushu University Hospital, Kyushu Cancer Center, Nagasaki University Hospital, and Kumamoto Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all of the patients who participated in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from all of the patients who participated in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T. Kiguchi reports research funds from SymBio Pharmaceuticals Limited. K. Izutsu reports personal fees from Janssen Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin Co., Ltd., and Eisai Co., Ltd. and research funds from AstraZeneca K.K., Abbvie, Eisai, Incyte Co., SymBio, Celgene Corporation, Novartis, Bayer, Janssen, Yakult, Kyowa Kirin, Ono, Zenyaku Kogyo, Daiichi Sankyo, Chugai, Beigene, and Genmab. H. Kato reports research funds from Zenyaku Kogyo, Chugai Pharmaceutical Co., Ltd., SymBio, Incyte, and Mundipharma and personal fees from SymBio. S. Rai reports personal fees from Chugai, Ono, and Janssen. J. Kuroda reports scholarship from Chugai. K. Ishizawa reports personal fees from Eisai, Novartis, Chugai, Celgene, Takeda Pharmaceutical Company Limited, Ono, IQVIA, Micron, Otsuka Pharmaceutical, Janssen, MSD, and Kyowa Kirin, SRD; research funds from Bayer, Otsuka, Pfizer, Sanofi, Abbvie, SymBio, Novartis, and IQVIA; and scholarship from Takeda. S. Ichikawa reports personal fee from AstraZeneca, and Chugai. K Ando reports research funds from Celgene, Novartis, and Astellas and scholarship from Chugai, Takeda, and Kyowa Kirin. M. Ogura reports personal fees from Meiji Seika Pharma. Y. Terui reports personal fees from Celgene, Janssen, MSD, Eisai, Ono, Takeda, Chugai, and Abbvie. K. Fukushima is an employee of SymBio. The rest of authors do not have any relationships to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}